Idorsia – Talk Bio

Satellos Advances Duchenne Pill Trial in Children; Idorsia Raises $81 Million

2 months ago talkbio0Tagged Child, Fund Raising, Idorsia, Indonesian language, Muscular Dystrophy, Duchenne, oral small-molecule therapy, Phase 2 clinical trial, SAT-3247, Satellos, Submission, United States Food and Drug Administration

Satellos; Duchenne muscular dystrophy; SAT-3247; Phase 2 clinical trial; children; FDA IND submission; oral small-molecule therapy; Idorsia; fundraising; biotech

Idorsia’s Restructuring Efforts Continue: Layoffs On Track Despite Delayed Sale of Hypertension Drug Tryvio

12 months ago talkbio0Tagged aprocitentan, cost-saving measures, financial sustainability, Hypertensive disease, Idorsia, layoffs, restructuring, Tryvio

Idorsia, Restructuring, Layoffs, Tryvio, Hypertension drug, Aprocitentan, Cost-saving measures, Financial sustainability

Idorsia Pursues Strategic Licensing Deal for TRYVIO Amid Restructuring Efforts

1 year ago talkbio0Tagged financial strategy, Idorsia, restructuring, Tryvio

Idorsia, TRYVIO, aprocitentan, licensing deal, layoffs, restructuring, financial strategy

FDA Greenlights Idorsia’s Aprocitentan (Tryvio) for Resistant Hypertension Patients

2 years ago talkbio0Tagged 12.5 mg, Approved, aprocitentan, aspects of adverse effects, Availability of, Clinical Trials, Combined Modality Therapy, Edema, Endothelin receptor antagonist, Idorsia, Intravascular systolic:Pressure:Point in time:Arterial system:Quantitative, Liquid substance, Precision - temporal, Recommended dosage, Resistant hypertensive disorder, Retention (Psychology), Second Half of 2024, Tryvio, Uncontrolled hypertension, United States Food and Drug Administration

FDA approval, Idorsia, Aprocitentan, Tryvio, Resistant hypertension, Endothelin receptor antagonist, Systolic blood pressure, Uncontrolled hypertension, Combination therapy, Clinical trials, PRECISION study, Recommended dosage: 12.5 mg, Availability: Second half of 2024, Edema and fluid retention side effects